IDENTIFICATION, CHARACTERISATION AND ROLE OF LEADER CELLS IN OVARIAN CANCER PROGRESSION
Dr Maree Bilandzic, Research Group Head
Metastasis Biology & Therapeutics Laboratory
Hudson Institute of Medical Research,
Clayton, Victoria, Australia
RESEARCHER PROFILE
Filmed in Clayton, Victoria, Australia | December 2024
Dr. Maree Bilandzic is a molecular cancer biologist dedicated to advancing the understanding and treatment of ovarian cancer (OC). Her research addresses critical gaps in OC treatment by investigating the mechanisms behind metastasis, chemotherapy resistance, and tumour recurrence. By utilising innovative methodologies and disease-representative models, Dr. Bilandzic has pioneered the identification and characterisation of leader cells (LCs)—a unique, stem-like subpopulation within tumours that plays a crucial role in OC progression.
LCs facilitate “collective invasion,” enabling tumour cells to spread by interacting with their environment and influencing immune responses. Importantly, Dr. Bilandzic’s research demonstrated that these LCs are resistant to standard therapies and become more prevalent following treatment. Despite their significance, there are currently no targeted therapies for LCs, highlighting the urgent need for novel therapeutic strategies.
Her work focuses on meeting the unmet clinical needs of patients with metastatic and therapy-resistant OC. By disrupting LCs, Dr. Bilandzic’s team has shown enhanced chemosensitivity, limited tumor spread, and altered immune responses—demonstrating the therapeutic potential of targeting LCs.
She has over $3.5 million in commercial funding and additional support exceeding $2 million from organisations such as the Ovarian Cancer Research Foundation, CASS Foundation, Fielding Foundation, Equity Trustees and Perpetual Impact grants. Dr. Bilandzic is well-positioned to expand her research into other epithelial cancers, aiming to develop effective treatments that can significantly improve patient outcomes across multiple cancer types. Key areas of focus include understanding LC roles in immune modulation, invasion, metastasis, and chemotherapy resistance.
-
World-first clinical trial improves patient outcomes for kidney transplants (2023)
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.
The lead-author of the study, was Royal Adelaide Hospital Nephrologist and University of Adelaide researcher, Dr Michael Collins.
-
Inner ear organoids for the study of human hearing and balance
Dr Jackie Ogier is an auditory neuroscientist, with a research focus on the molecular biology of hair cells, the specialised sensory receptors in the ear that detect sound and balance. She is a postdoctoral research fellow in the laboratory of A/Prof Bryony Nayagam, supported by a prestigious Passe and Williams foundation fellowship.
Dr Ogier’s experience broadly spans the genetics of hearing loss, disease modelling, micro dissection, primary cell culture, stem cell culture, organoids, and proteomics. Overall, she aims to generate knowledge of hearing and vestibular sensory biology.
-
Integrated Oral Health Care
Dr Ajesh George is a Professor of Interprofessional Oral Health in the School of Nursing and Midwifery, Western Sydney University (WSU) and Honorary Professor in the School of Dentistry at The University of Sydney. He is a dentist with extensive experience in integrated oral health care and is a renowned expert globally in providing oral health training to non-dental professionals and translating oral health guidelines into their practice. Dr George is also the Director and Co-founder of the “Australian Centre for Integration of Oral Health” (ACIOH) which is a leading national research centre led by WSU in collaboration with various partners including universities, health services and professional organisations.
